Disease · EFO_0020988

blood transfusion

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. blood transfusion. Diseases, record EFO_0020988. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0020988

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: blood transfusion; Open Targets
Open Targets ID: EFO_0020988; Open Targets
NCI Thesaurus: C15192; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 7 drugs, from TTD; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HETASTARCH	CHEMBL2108448		Approval	TTD	1	0	0	Drugs and targets
POLYGELINE	CHEMBL2108135	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
AMINOCAPROIC ACID	CHEMBL1046	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IRON ISOMALTOSIDE 1000	CHEMBL4298046		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTALYTE	CHEMBL2104840	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
ROMYELOCEL-L	CHEMBL3137339	Cell	Phase 2	TTD	1	0	0	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PLG	Plasminogen	2	Plasminogen inhibitor	Phase 3	https://conductscience.org/library/genes/5340	Drugs and targets
PLAT	Tissue-type plasminogen activator	1	Tissue-type plasminogen activator inhibitor	Phase 3	https://conductscience.org/library/genes/5327	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02043132	Tranexamic Acid in Reverse Total Shoulder Arthroplasty	Phase 2/3	116	2017-06-19	Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02655653	Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery	Phase 3	114	2020-06-16	Bleeding	AMINOCAPROIC ACID, TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01370460	Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty	Phase 2	101	2013-07-09	Acute Blood Loss Anemia, Osteoarthritis, Knee	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02972294	HiFIT Study : Hip Fracture: Iron and Tranexamic Acid	Phase 3	419		Hip Fractures Pathologic, Anemia	IRON ISOMALTOSIDE 1000, TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04811313	Tranexamic Acid in Pediatric Undergoing Proximal Femoral Osteotomies and/or Acetabular Osteotomy	Not applicable	400		Intraoperative Blood Loss, Pediatric, Orthopedic Disorder	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01881568	Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA	Phase 3	79		Blood Loss	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT05024253	Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.	Phase 3	48		Ewing Sarcoma of Bone, Osteosarcoma	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Diagnosis of Renal Dysfunction Post-operation	3 of 56	2 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest	11 of 56	5 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Number of Participants With Confirmed Diagnosis of Seizure	0 of 56	0 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Diagnosis of Myocardial Infarction Post-operation	1 of 56	1 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Reoperation	3 of 56	4 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Number of Participants With Confirmed Diagnosis of Stroke	2 of 56	2 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Mortality Within 30 Days Post-operation	1 of 56	1 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): deaths from any cause	1 of 56	1 of 58	114	NCT02655653	Trial comparisons
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): serious adverse events	20 of 56	14 of 58	114	NCT02655653	Trial comparisons
Tranexamic Acid vs Normal Saline: Number of Participants Experiencing Deep Vein Thrombosis	0 of 53	0 of 49	102	NCT02043132	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38689774	DERIVED	1	PubMed
37524101	DERIVED	1	PubMed
33781988	DERIVED	1	PubMed
33455926	DERIVED	1	PubMed
25471907	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0020988

GET https://conductscience.org/api/diseases/v1/EFO_0020988/drugs

API reference For AI assistants